Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shuren Highlights CDRH Actions To Ease Trial Burdens On Capitol Hill

This article was originally published in The Gray Sheet

Executive Summary

CDRH Director Jeffrey Shuren participated in the first roundtable of a newly launched House Energy and Commerce Committee initiative to accelerate drug and device development. He emphasized the device center’s recent proposals to minimize pre-market data collection with postmarket controls, and supported the promise of clinical trial networks.

You may also be interested in...



FDA Will Face Reforms, Oversight In Republican Congress – Analysts

Election gains will embolden Republicans to put FDA in Congress’ oversight “crosshairs,” as members of key Senate and House panels scrutinize how the agency is using its resources. Reforms could also come soon as part of the ongoing 21st Century Cures initiative.

FDA Will Face Reforms, Oversight In Republican Congress – Analysts

Election gains will embolden Republicans to put FDA in Congress’ oversight “crosshairs,” as members of key Senate and House panels scrutinize how the agency is using its resources. Reforms also could come soon as part of the ongoing 21st Century Cures initiative.

FDA Will Face Reforms, Oversight In Republican Congress, Analysts Say

Election gains by Republicans will embolden Congress to put FDA in its oversight “crosshairs,” as members of key Senate and House panels scrutinize how the agency is using its resources. Reforms could also come soon as part of the ongoing 21st Century Cures initiative.

Related Content

UsernamePublicRestriction

Register

MT032979

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel